News

News

Hikma receives favourable court ruling for its generic Vascepa®

News

News

Hikma delivers strong first half performance and raises full year guidance

Update

Update

Hikma update regarding COVID-19

Our H1 2020 results

Watch this short video summary of the highlights of our interim results.

Case study

Case study

Our support and impact for the Healthy Kitchen Project

Case study

Case study

Our support and impact; improving patient’s access to ritonavir

Insight

Insight

Two ways to minimise the impact of COVID-19 on vulnerable communities

Sustainability news

Sustainability news

Hikma improves performance in FTSE4Good Index

Find out more

Who we are. We make high quality medicines and make them accessible to the people that need them.

Corporate social responsibility

Corporate social responsibility

Hikma launches employee matching donation campaign to support local US food banks and pantries

Find out more

Find out more

Our commitment to sustainability

Find out more

Find out more

We develop, manufacture and market nearly 700 quality branded and non-branded generic medicines worldwide.